Content Type: Article

  • FDA Seeks Comments on Updates to MoCRA Guidance on Registration, Listing of Cosmetic Product Facilities

    FDA Seeks Comments on Updates to MoCRA Guidance on Registration, Listing of Cosmetic Product Facilities

    ARTICLE / CLIENT ALERT

    FDA Seeks Comments on Updates to MoCRA Guidance on Registration, Listing of Cosmetic Product Facilities

    December 26, 2024

    Read time: 4 min

    Key takeaways
    Overview

    On December 11, 2024, the US Food and Drug Administration (FDA) updated its Guidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products. As discussed in our previous On the Subject, FDA released the original version of the final guidance in December 2023 as required by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). MoCRA introduced several new requirements for cosmetic product facilities, and the final guidance provided key information about who must register, what information is required, how and when to submit information, and available exemptions. The final guidance also included frequently asked questions (FAQs) in Appendix B, designed to help industry stakeholders understand and comply with MoCRA requirements, which the FDA began enforcing on July 1, 2024.

    The updated guidance builds on the earlier issued guidance, with the addition of new registration and listing FAQs. FDA has solicited comments about the updates to the guidance by January 13, 2025.

    In depth

    MoCRA, signed into law in 2023, introduced new requirements for cosmetic companies, including:

    • Facility registration and product listing
    • Good manufacturing practices (GMPs)
    • Safety data and adverse event reporting
    • Labeling requirements (domestic contact information, allergens, and professional use labels).

    Most importantly, under MoCRA, FDA has enhanced enforcement powers, such as inspecting facilities, requesting recalls, and suspending registrations if products pose significant health risks.

    Key MoCRA Deadlines

    • Facility registration and product listing: July 1, 2024.
    • Update responsible person contact information: December 29, 2024.
    • FDA GMP regulations and PFAs report: December 29, 2025.

    Key Definitions

    The updated FAQs use the following definitions regarding the implementation of the registration and product listing requirements of Section 607 under the Food, Drug, and Cosmetic Act:

    • US agent: A US-based individual or entity acting as FDA contact for foreign facilities.
    • FEI: FDA establishment identifier, a unique registration number for facilities.
    • Cosmetic product: A specific preparation of cosmetic ingredients for a finished product.
    • Facility: Any establishment that manufactures or processes cosmetic products distributed in the United States.

    FAQs

    FDA added three FAQs in Appendix B of the guidance. These three new FAQs are open to comments from stakeholders. While FDA will accept comments on any guidance document at any time, it requested comments on the new FAQs by January 13, 2025.

    Below are concise summaries of the new FAQs; for further detail, please consult Appendix B of the updated guidance.

    20. What are the responsibilities of a US agent?

    • Assist FDA in communications with the foreign establishment.
    • Respond to questions about the foreign establishment’s products imported into the US.
    • Help FDA schedule inspections of the foreign establishment.
    • Receive information or documents from FDA on behalf of the foreign establishment when direct contact is not possible.

    21. Can nearby buildings share one FEI number?

    • Multiple buildings within three miles of one another can share one FEI number if they are part of the same business, are under the same local management, and can be inspected together.
    • The cosmetic product facility registration system allows one registration per FEI number, even if it includes multiple buildings.

    22. Do free samples or gifts require product listing?

    • Yes, generally. A product listing must be submitted for each cosmetic product, including free samples or gifts.
    • Exemptions apply for samples provided for research and development or within the industry, not intended for consumer use.

    Key Takeaways

    FDA’s addition of three new FAQs to the final guidance offers an opportunity for stakeholders to provide feedback on MoCRA implementation. Comments on these updates should be submitted by January 13, 2025.

    If you are interested in submitting comments or would like additional information on FDA’s regulation of cosmetic products, contact the authors of this article or a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Jeff Weinstein

    Counsel

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • IRS Planned Outage

    IRS Planned Outage

    ARTICLE / CLIENT ALERT

    IRS Planned Outage

    December 24, 2024

    Read time: 2 min

    Key takeaways
    Overview

    The IRS has posted a notice that their online service to apply for EINs will be unavailable from about 3pm EST Dec. 27, 2024, to 7am EST Jan. 2, 2025. During that time, we will not be able to apply for EINs for domestic or foreign entities.

    Accordingly, any entity that needs an EIN before year end should apply within the next three days, as we cannot predict the availability of IRS officials to issue EINs by other means. As a reminder, only one EIN can be issued per day in respect of a responsible party (typically, an individual who is the general partner, managing member or principal officer of the electing entity).

    Read the IRS service outage announcement.

    In depth
    Authors
    More insights

  • Five Key Takeaways From the Proposed PTEP Regulations

    Five Key Takeaways From the Proposed PTEP Regulations

    ARTICLE / CLIENT ALERT

    Five Key Takeaways From the Proposed PTEP Regulations

    December 23, 2024

    Read time: 8 min

    Key takeaways
    Overview

    Taxpayers have been eagerly awaiting, and the US Department of the Treasury (Treasury) and the Internal Revenue Service (IRS) have been promising to provide, rules addressing the previously taxed earnings and profits (PTEP) of foreign corporations. On November 30, 2024, the Treasury and the IRS made good on their promise. The proposed PTEP regulations are generally welcome news for taxpayers seeking certainty about long-standing issues, including the treatment of mid-year distributions, Section 961(c) basis, and partnerships that hold foreign corporations. However, those welcome developments come at the cost of substantial complexity and several taxpayer-unfavorable provisions. In this On the Subject, we provide a brief overview of PTEP and why it matters and share five key takeaways from the proposed regulations.

    In depth

    Overview of PTEP

    The PTEP rules provide that when earnings of a foreign corporation have been included in the US shareholder’s gross income, when those earnings are distributed, they are excluded under Section 959(a) from the US shareholder’s gross income to ensure the same earnings are not subject to US taxation twice. Under Section 959(b), PTEP distributions from a lower-tier controlled foreign corporation (CFC) to an upper-tier CFC are also excluded from the upper-tier CFC’s income for purposes of determining the upper-tier CFC’s gross income. The Section 961 rules provide for adjustments in the US shareholder’s basis in CFC stock to prevent taxpayers from obtaining a loss when the stock is sold before PTEP is distributed. Under Section 961(a), Subpart F and global intangible low-taxed income (GILTI) inclusions increase the US shareholder’s basis in the CFC. Under Section 961(b), distributions decrease it. Section 961(c) provides that similar adjustments are made to an upper-tier CFC’s basis in a lower-tier CFC but only for purposes of determining the amount included under Section 951 in the gross income of a US shareholder.

    The PTEP rules have become much more important to US-based multinationals since the Tax Cuts and Jobs Act of 2017 (TCJA) vastly increased the amount of foreign corporations’ earnings subject to current US taxation as GILTI. Post-TCJA, some shareholders may even prefer a distribution of untaxed earnings and profits, which may qualify for the Section 245A dividends received deduction and does not require a Section 961(b) reduction in basis.

    The current Section 959 PTEP regulations are from 1965 and do not address many key issues. In 2006, the Treasury and the IRS issued proposed PTEP regulations, but the proposed regulations did not expressly permit taxpayer reliance, and the rules were withdrawn in 2020.

    The newly proposed rules are complex, but here are five key takeaways to keep in mind:

    1. They Are Generally Prospectively Effective and Cannot Be Relied Upon Now (But Can Be Relied on Retroactively if and When the Rules Are Finalized).

    Most of the regulations will be effective for taxable years ending on or after the date the regulations are finalized.

    Taxpayers are not allowed to rely on the proposed regulations prior to them being finalized. The Treasury has indicated that they did not allow taxpayers to rely on the regulations while in proposed form because of the complexity of the rules and the fact that they introduce new concepts not previewed in prior guidance. The regulations may also be changed before finalization after considering taxpayer comments. However, once the rules are finalized, taxpayers will be able to elect to apply them retroactively to any open tax years as long as they apply all of the proposed rules in full and are consistent about applying the rules to related corporations.

    The rules include transition rules to bridge years for which the regulations are effective with prior years.

    2. They Require Shareholder and Foreign-Corporation-Level Accounting.

    The proposed PTEP rules are quite complex in that they require PTEP to be tracked at both the US shareholder and the foreign corporation level. In addition to PTEP, shareholders must track (1) a US dollar basis pool, which is their US dollar basis in the original PTEP inclusion for purposes of recognizing foreign exchange gain or loss under Section 986(c), and (2) a PTEP tax pool, which is the US dollar basis of foreign income tax pools associated with the US dollar basis pool.

    The proposed rules largely follow the ordering rules set forth in Notice 2019-01, which was released in late 2018. These rules generally require that 10 different PTEP groups be tracked within each Section 904(d) foreign tax credit category on an annual basis. To slightly simplify compliance, taxpayers may elect to combine years within a PTEP group and Section 904(d) foreign tax credit category, rather than tracking each year separately.

    These ordering rules include a rule to treat Section 965(a) and Section 965(b) PTEP, which resulted from the one-time transition tax as part of the TCJA, as being distributed first before other types of PTEP (even PTEP earned in a more recent tax year). The rule was aimed at reducing complexity by allowing Section 965 PTEP to come out first so corporations and the IRS would not have to track Section 965 PTEP groups in perpetuity.

    The proposed PTEP regulations set forth rules for when adjustments to PTEP and associated stock basis are made. One key rule is that increases to PTEP for GILTI or Subpart F inclusions are done at the beginning of the year, so PTEP (and the associated stock basis) is available for mid-year distributions.

    3. They Adopt a Share-by-Share Approach to Section 961 Basis

    The proposed regulations provide that, unlike PTEP accounts, section 961 basis is specific to particular shares or items of property, such as partnership interests. The timing of basis adjustments is intended to generally match the timing of adjustments to PTEP accounts. The share-by-share approach to section 961 basis differs from the proposed regulations’ approach to section 959, which does not tie particular dollar basis pools of PTEP to particular shares held by a US shareholder. In certain cases, this mismatch could give rise to a shareholder recognizing gain on some shares even though the shareholder has unrecovered basis on other shares, a result arguably inconsistent with the repatriation-facilitating goal of the TCJA. Taxpayers should consider whether they have “lumpy” basis in CFC stock that could give rise to such a mismatch. Post-TCJA, a distribution of PTEP (historically a good attribute) may be less favorable in certain circumstances than a distribution of untaxed earnings and profits that qualifies for the Section 245A dividends received deduction and generally does not require a reduction in basis.

    4. They Provide Detailed Rules for Lower-Tier Basis

    In addition to providing rules for Section 961(a) basis, the proposed regulations also provide rules for lower-tier basis, including both (1) “derived basis” (a new term applicable to shares or partnership interests owned by a partnership and distinct from the partnership’s common basis in such shares or partnership interests), and (2) Section 961(c) basis (applicable to shares of a lower-tier CFC owned by an upper-tier CFC). The proposed regulations provide that both derived basis and Section 961(c) basis can be negative. Derived basis can be negative to the extent of common basis; amounts exceeding the common basis are recognized as gain. Taxpayers should be careful to track Section 961(c) basis – yet another separate type of basis or account to track – to ensure that “negative” Section 961(c) basis is not inadvertently triggered as gain, which can even occur in connection with transactions that are otherwise nonrecognition transactions.

    5. They Don’t Address Certain Key Items

    As expected, the proposed regulations do not address certain key items, such as whether/how PTEP transfers from one shareholder to another in Section 304 transactions, redemptions, and most nonrecognition transactions, such as 351 transactions and liquidations. The Treasury and the IRS plan to address those issues in a second tranche of PTEP guidance. The proposed regulations also do not address what happens to Section 961(c) basis when an upper-tier CFC inbounds to the United States (e.g., whether the Section 961(c) basis can be used as “regular” basis), which Notice 2024-16 permits in the case of “covered inbound transactions.”

    Conclusion

    The proposed PTEP regulations cover a lot of ground. The Treasury and the IRS have requested comments on several provisions and encourage taxpayers to provide comments on whether the proposed regulations get it right. Taxpayers should study the rules carefully and consider whether there are provisions worth asking the Treasury and the IRS to reconsider.

    Authors

    Elizabeth Chao

    Partner

    Chicago

    Timothy S. Shuman

    Partner

    Washington, DC

    More insights

  • Important Update – Corporate Transparency Act: Reporting Reinstated by Appellate Court and FinCEN Extends Deadline to Jan. 13

    Important Update – Corporate Transparency Act: Reporting Reinstated by Appellate Court and FinCEN Extends Deadline to Jan. 13

    ARTICLE / CLIENT ALERT

    Important Update – Corporate Transparency Act: Reporting Reinstated by Appellate Court and FinCEN Extends Deadline to Jan. 13

    December 23, 2024

    Read time: 4 min

    Key takeaways
    Overview

    On Dec. 23, 2024, the US Court of Appeals for the Fifth Circuit stayed the nationwide preliminary injunction[1] that enjoined enforcement of the Corporate Transparency Act (“CTA”) and its implementing regulation (31 C.F.R. §1010.380).[2] Reporting companies are now required to file beneficial ownership information reports (“BOI Reports”) with the US Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) while the outcome of the government’s ongoing appeal of the District Court’s order is pending.

    In light of today’s decision and given there are only a few days remaining until the Jan. 1 compliance date, FinCEN quickly issued an updated alert to its beneficial ownership information webpage extending the BOI Report filing deadlines as follows:

    • Reporting companies that were created or registered prior to Jan. 1, 2024 have until Jan. 13, 2025 to file their initial beneficial ownership information reports with FinCEN. (These companies would otherwise have been required to report by Jan. 1, 2025.)
    • Reporting companies created or registered in the United States on or after Sept. 4, 2024 that had a filing deadline between Dec. 3, 2024 and Dec. 23, 2024 have until Jan. 13, 2025 to file their initial beneficial ownership information reports with FinCEN.
    • Reporting companies created or registered in the United States on or after Dec. 3, 2024 and on or before Dec. 23, 2024 have an additional 21 days from their original filing deadline to file their initial beneficial ownership information reports with FinCEN.
    • Reporting companies that qualify for disaster relief may have extended deadlines that fall beyond Jan. 13, 2025. These companies should abide by whichever deadline falls later.

    The BOI Report filing deadline for reporting companies created/registered on or after Jan. 1, 2025 has not changed. Those reporting companies will have 30 days from receiving notice of creation/registration to file a BOI Report.

    Further appellate review – at either the Fifth Circuit or the United States Supreme Court – could reinstate the District Court’s nationwide preliminary injunction or otherwise impact firms’ filing obligations. We will continue to monitor for developments related to this case, including whether the Fifth Circuit decision gets reversed and whether the Justice Department, the Treasury Department or FinCEN issues any additional guidance in order to assist clients in navigating their CTA obligations.

    Authored by Melissa G.R. Goldstein,  Betty Santangelo, Michael S. Didiuk, Jessica Romano, Kyle B. Hendrix and Bryson Kern.

    For assistance in navigating the CTA’s reporting requirements, please contact one of the authors or your attorney at Schulte Roth & Zabel.


    [1] For more information on the nationwide preliminary injunction, please see our prior Alerts: “Corporate Transparency Act Update: Government Challenges Nationwide Preliminary Injunction & FinCEN Clarifies That Reports Are Voluntary”; and “Corporate Transparency Act Update: Nationwide Preliminary Injunction Enjoining Enforcement”.

    [2] Texas Top Cop Shop, Inc. v. Garland, No. 24-40792 (5th Cir. Dec. 9, 2024). The Fifth Circuit order stays the nationwide preliminary injunction pending a determination by the Fifth Circuit on the government’s appeal.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2024 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    More insights

  • Fifth Circuit Vacates SEC Order Approving Nasdaq Board Diversity Rules

    Fifth Circuit Vacates SEC Order Approving Nasdaq Board Diversity Rules

    ARTICLE / CLIENT ALERT

    Fifth Circuit Vacates SEC Order Approving Nasdaq Board Diversity Rules

    December 20, 2024

    Read time: 3 min

    Key takeaways
    Overview

    On December 11, 2024, the US Court of Appeals for the Fifth Circuit vacated the US Securities and Exchange Commission’s (SEC) order approving The Nasdaq Stock Market LLC’s (Nasdaq) board diversity rules, holding that the rules did not relate to the purpose of the Securities Exchange Act of 1934 (Exchange Act) nor did the SEC have the authority to approve the rules.

    In depth

    In August 2021, the SEC approved Nasdaq’s proposed diversity rules, which required issuers listed on the exchange to:

    • Have, or explain why it does not have, at least two directors who are diverse, including at least one director who self-identifies as female and at least one director who self-identifies as an underrepresented minority or LGBTQ+ (Rule 5605(f))
    • Annually disclose statistical information about the self-identified diversity characteristics of the issuer’s board of directors in a board diversity matrix (Rule 5606).

    The rules were previously upheld by a Fifth Circuit panel in Alliance for Fair Board Recruitment v. SEC (5th Cir. Oct. 18, 2023).

    The Fifth Circuit, sitting en banc, reheard the case and vacated the SEC’s order approving the rules in a 9-8 decision. The majority opinion held that the Nasdaq rules did not relate to the purposes of the Exchange Act, which are “primarily about limiting speculation, manipulation, and fraud, and removing barriers to exchange competition.”[1] The Court further reasoned that the SEC lacked clear congressional authorization to approve these rules under the major questions doctrine, which requires clear and express congressional authorization to administrative agencies when such agencies regulate areas of vast economic and political significance.[2]

    Section 19 of the Exchange Act requires that the SEC approve any proposed rule changes by self-regulatory organizations, such as Nasdaq, with limited exceptions. With the Fifth Circuit vacating the SEC’s order approving the diversity rules, the rules are no longer in effect and Nasdaq-listed issuers will no longer be required to comply with them. As a result, the board diversity matrix that would otherwise have been required to be included in next spring’s annual proxy statement for calendar year companies is no longer required and/or posting such matrix on company websites is no longer required.

    Notably, although the New York Stock Exchange (NYSE) does not have diversity disclosure rules equivalent to the now-repealed Nasdaq regulations, DiversIQ reported that 55.5% of NYSE-listed S&P 500 companies met the previously required Nasdaq reporting standards. Further, 97.6% and 95.3% of all S&P 500 companies have disclosed aggregate gender and race data about their boards, respectively.[3]

    A Nasdaq representative expressed disagreement with the Fifth Circuit’s ruling but confirmed that the exchange does not intend to appeal the decision. Meanwhile, an SEC spokesperson stated that the agency is currently reviewing the ruling and will determine the appropriate next steps.

    Authors

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Heidi J. Steele

    Partner

    Chicago

    Eric Orsic

    Partner

    Chicago

    Riley O'Farrell

    Associate

    Chicago

    More insights

  • FTC Targets Price Discrimination With New Robinson-Patman Act Lawsuit

    FTC Targets Price Discrimination With New Robinson-Patman Act Lawsuit

    ARTICLE / CLIENT ALERT

    FTC Targets Price Discrimination With New Robinson-Patman Act Lawsuit

    December 20, 2024

    Read time: 12 min

    Key takeaways
    Overview

    Background on the Case

    On December 12, 2024, following a nearly two-year-long investigation, the Federal Trade Commission (FTC) initiated its first litigation under the Robinson-Patman Act (RPA)[1] in more than two decades. The FTC sued Southern Glazer’s, a large wine and spirits distributor, alleging the company charged higher prices to smaller retailer customers than it did to large chains, violating the RPA.

    The litigation, filed in the last days of the Biden administration’s antitrust regime, may ultimately end with a whimper under the next administration. But for companies managing modern pricing systems, the complaint and the controversy surrounding it provide important insights into how complainants could seek to advance RPA suits in today’s retail environment. The complaint illustrates how current FTC leadership intended to operationalize its new focus on price discrimination and provides a roadmap for how state regulators and private plaintiffs can litigate the issue regardless of how the FTC proceeds under the new administration. Perhaps even more useful, the dissents filed by FTC Commissioners Melissa Holyoak and Andrew Ferguson suggest a blueprint for a legal response to future actions that may resonate with other regulators – and more importantly, with federal and state judges.

    In depth

    The Complaint

    The FTC’s complaint set out to establish the basic elements of RPA violations, alleging that Southern Glazer’s sold the same products at different prices to customers in competition with one another downstream, causing harm to retailers paying higher prices. The FTC also alleged that the usual range of defenses available to sellers under the RPA do not apply.

    Discriminatory Pricing

    The FTC alleged discrimination in several standard pricing and discounting mechanisms, including:

    • “High-volume quantity discounts”
    • “Cumulative quantity discounts”
    • “Scan rebates”
    • Other forms of price consideration that were redacted from the complaint.

    The FTC also alleged that Southern Glazer’s accepts discounts in return for providing discriminatory pricing to its own retailer customers. Additionally, the FTC alleged that the discounting involved is problematic because it is “not associated with any efficiency derived from the differing method or quantities in which the wine or spirits are manufactured, sold, or delivered to the favored large chains.”

    Defenses

    The FTC’s complaint sought to head off the most common defenses available to companies accused of violating the RPA: the functional availability defense, justification by cost savings, and changing conditions.

    The FTC alleged that Southern Glazer’s discounting could not be justified under the functional availability defense (i.e., that the discounts were made available to customers who allegedly paid the higher price) because “the deepest available discounts” require “purchase levels that only a few specific large chain customers can attain,” or that could be earned only by “combining purchases across many stores or by utilizing [customer-owned] warehouses.” The FTC further sought to forestall the functional availability defense, alleging that independent retailers were often unaware and “not informed about” the available discounts “even when it may be logistically feasible for the independent retailer to participate in the deal.”

    The FTC also alleged that Southern Glazer’s lower cost to serve the allegedly favored retailers did not justify the price differences because “the pricing differentials between favored and disfavored retailers exceed any cost savings achieved” by Southern Glazer’s when selling to “favored national chains.”

    In boilerplate language, the FTC further alleged that price differences were not justified by attempts by Southern Glazer’s to meet competition from other distributors nor as a response to changing conditions or marketability, such as discounting for older, seasonal, or discontinued merchandise.

    Harm to Competition

    The FTC goes on to allege that the price differences were sufficient to enable favored chain purchasers to sell beverage products at lower retail prices than their smaller retail competitors paid to acquire the products from Southern Glazer’s at wholesale, costing smaller retailers sales and profits.

    Implications of the Litigation

    Significant compliance concerns were raised two years ago when it first became known that the FTC was investigating multiple companies and industries regarding pricing practices and was seeking to reinvigorate pricing discrimination enforcement under the RPA. Two years later, the filing of this complaint went off like a firecracker (but may end up a damp squib).

    Incoming FTC Republican Majority Disfavors the Approach

    The complaint drew sharp rebukes from current-minority Republican Commissioners Ferguson and Holyoak.

    Commissioner Ferguson, recently tapped to be the next FTC chair, took issue both with the FTC’s decades-long decision not to enforce the RPA on policy grounds and on its decision to attempt to enforce the RPA in this case. He argued that “Southern [Glazer’s] appears likely to succeed on a cost-justification defense” and laid out a broad vision of the cost justification defense, anticipating that:

    • In many price discrimination cases “the differences in costs associated with serving large chain stores rather than independents” are the source of price differentials, which should therefore be justified and
    • “[I]solated instances of unjustified price discrimination do not violate the [RPA].”

    Commissioner Ferguson also argued that the FTC will struggle to prove that Southern Glazer’s conduct caused competitive injury stating, “[c]onsumers may purchase spirits from large retail chains rather than in small liquor stores because of lower prices. But they may also do it because of some other feature of the favored retailers’ business – for example, the convenience of buying alcohol alongside other household goods and groceries.” He argued that the FTC’s approach to competitive injury is inconsistent with the plain text of the RPA and how courts interpret nearly identical language in other federal antitrust laws.

    Commissioner Holyoak’s dissent, which was 88 pages compared to the complaint’s 25 pages, reads as an omnibus of objections to this application of the RPA. Along with objections like those in Commissioner Ferguson’s dissent, she argues that the FTC’s complaint does not sufficiently allege competitive harm for two reasons:

    • The RPA’s history and early enforcement indicates that the RPA should be interpreted only to prohibit price discrimination resulting in harm to competition (i.e., consumers) rather than competitors.
    • Competitive harm cannot be inferred from differential pricing alone (essentially rejecting the proposition that such price differences are sufficient to support such an inference, as decided in the Supreme Court of the United States’ Morton Salt case discussed further below).

    Commissioner Holyoak’s dissent emphasized that RPA enforcement harms consumers and small businesses and results in reduced discounting and higher prices.

    Further, Commissioner Holyoak took the position that RPA enforcement in the alcohol industry is particularly troublesome. According to her dissent, heavy state regulation of alcohol and its strong influence on pricing, along with the prohibition of vertical integration under the three-tier system, mean that in-state sales by an independent distributor like Southern Glazer’s “are not ‘in commerce,’” so they are not subject to the RPA.

    The FTC’s approach to the RPA is uncertain, in part because of President-elect Donald Trump’s announcement of Mark Meador, who has been an outspoken advocate of RPA enforcement, as the future third Republican commissioner. Meador’s nomination makes it difficult to predict whether the FTC will continue to pursue RPA enforcement, regardless of the positions set out by Commissioners Ferguson and Holyoak. Whether Meador applies his previous statements on RPA enforcement in practice remains to be seen, but he has made clear statements contrary to the themes in Commissioners Ferguson and Holyoak’s dissents, including vehemently disagreeing with the assertion that the RPA should not be enforced by the FTC on the basis that its commissioners believe it is bad policy.

    Key Takeaways

    With the change in administration imminent, there is uncertainty as to the future of the case against Southern Glazer’s. As catalogued in the two dissents, Commissioners Holyoak and Ferguson, who will sit in the FTC’s Republican majority, are unlikely to continue to support the case in its current form. However, it is much less certain as to how future-Commissioner Meador will approach the case, meaning we may not know how the case will proceed for at least a few months after Meador is confirmed (he will need to be briefed on the factual record). Regardless of the outcome, the case offers valuable insights into future RPA enforcement. It highlights how state government enforcers and private plaintiffs could seek to bring new price discrimination suits, even in the absence of federal action. Consequently, this litigation is important for companies engaged in some form of differential pricing (as many are) in several ways:

    A Roadmap for RPA Claims

    The complaint closely resembles many traditional RPA complaints and provides a solid roadmap for the architecture of a lawsuit based on a price discrimination theory. Companies may find it useful for visualizing how a plaintiff or regulator may allege the elements of price discrimination, how pleadings allege that potential defenses do not apply, and as an illustrative tool to evaluate and strengthen current pricing programs.

    Viable Defenses in Future Enforcement

    Commissioners Holyoak and Ferguson identified several potential defenses not frequently used today that could be advanced to defend future suits. Given judicial hostility to RPA cases generally and the possibility that these defenses will be more persuasive to regulators in the future, companies should consider preparing for future RPA cases by developing evidence supporting such defenses, including:

    • Cost Justification
      • This defense has fallen out of favor because it has been interpreted to require precise accounting for specific differences in a seller’s costs to serve a favored account. Commissioners Holyoak and Ferguson, however, suggest this specificity may not be required. As Commissioner Ferguson put it, “many . . . price differentials . . . are due to the differences in costs associated with serving large chain stores rather than independents. Large orders, infrequently delivered in bulk to loading docks at central distribution centers, are less costly per unit to deliver than small orders, frequently delivered to individual stores.”
      • Companies may consider identifying what broad savings are associated with accounts to which they offer favorable pricing and potential sources of information that might support a cost justification in a future RPA investigation or suit, even if they are not able to quantify these savings with absolute precision with respect to a specific account.
      • For distributors, Commissioners Holyoak and Ferguson argue that volume discounts manufacturers offer to distributors on sales intended for resale to large accounts are cognizable cost savings for the purpose of a cost justification defense. Distributors may identify systematic ways to track savings they receive from manufacturers that are “earned” by a resale customer’s purchase volume or other characteristics to bolster such a defense.
    • Meeting Competition
      • The meeting competition defense is most often used when a seller has concrete evidence that lower pricing was granted to “meet but not beat” a specific lower competitive offer to a customer.
      • Commissioner Holyoak suggests that simple evidence that discounting resulted from fear of customer switching may suffice: “Southern Glazer’s has presented substantial evidence that both suppliers and retailers routinely threaten to switch – and do actually switch – to rival distributors. Efforts to defend against pricing challenges from Southern Glazer’s competitor distributors appears to have animated Southern Glazer’s pricing strategy.”
      • Companies may develop ordinary-course evidence that fear of customer switching and loss of sales drive discounting decisions – even where it is not possible to document a response to a specific competitive offer – to improve the prospects of a meeting competition defense

    The RPA’s Jurisdictional Limits May Place Intrastate Sellers in Regulated Industries Outside of the RPA’s Reach

    Commissioners Holyoak and Ferguson take the position that Sothern Glazer’s sales to retailers do not take place “in commerce” (across state lines). Although this defense may be of limited use to manufacturers and in industries in which resales routinely cross state lines, independent alcohol distributors (i.e., those not “vertically integrated” with manufacturers) may be able to reduce RPA risk by establishing that their sales are “in-state” and do not take place in interstate commerce.

    Competitive Harm May Require a Showing Beyond Differentiated Pricing

    Although liability under the RPA depends on a showing of “competitive harm,” traditional RPA analysis permitted plaintiffs to make that showing via a shortcut: the “Morton Salt inference.” In those cases, adequate harm could be inferred by showing a sustained difference in prices over time, which required defendants to mount complex factual defenses demonstrating that plaintiffs did not, in fact, lose sales to favored purchasers.

    Both Commissioners Ferguson and Holyoak contend that this analysis is incorrect and that mere inferences of harm to disfavored competitors are not the kind of “competitive harm” the RPA means to prevent. Both commissioners would instead require evidence showing broader harm to competition (i.e., harm to consumers from differential pricing). Under this interpretation, the RPA would only condemn price discrimination that is “predatory” – intended to destroy a competitor so that the discriminator could later raise prices unchecked.

    This suggests that companies may defend themselves from RPA claims by marshaling evidence that demonstrates that their discounting is procompetitive – intended to lower consumer pricing and increase sales rather than to drive a competitor out of business.

    Conclusion

    The FTC’s lawsuit against Southern Glazer’s – and the full-throated dissents filed by Commissioners Ferguson and Holyoak – suggest a turning point in RPA defense strategy. Although the FTC’s complaint was intended to reinvigorate federal RPA enforcement, based on traditional interpretations of the RPA from the 1960s and 1970s, the dissents more likely point the way forward in price discrimination law as they are consistent with decades of judicial skepticism of RPA claims.

    Many companies have thrown up their hands in despair at the idea of legal risk under the RPA. They are unable to charge all their customers identical prices because of competitive conditions and the economic realities of economies of scale, but the “letter of the law” established in long-dormant RPA jurisprudence suggest they are at constant risk of being investigated or sued for these rational pricing practices.

    Now those companies may have a more promising path to enable their businesses to compete while pursuing strategies to curb ever-present RPA risk. They can (1) document generalized evidence justifying discounting to serve some customers, (2) ensure that communications and other documents reflect that discounting is driven by the need to compete vigorously with aggressive competitors, and (3) show that discounting drives competition and lower prices to the benefit of consumers (rather than being intended to curtail competition by harming competitors). Some companies may also be able to show that their businesses are essentially local and were never intended to be within the scope of the RPA – particularly in regulated industries like alcohol, where state and local rules proscribe true interstate commerce.

    Authors

    Gregory E. Heltzer

    Partner

    Washington, DC

    Lisa P. Rumin

    Partner

    Washington, DC

    Ryan C. Tisch

    Partner

    Washington, DC

    Royce E. Brosseau

    Associate

    Washington, DC

    More insights

  • FDA Issues Final Guidance on Predetermined Change Control Plans for AI-Enabled Devices

    FDA Issues Final Guidance on Predetermined Change Control Plans for AI-Enabled Devices

    ARTICLE / CLIENT ALERT

    FDA Issues Final Guidance on Predetermined Change Control Plans for AI-Enabled Devices

    December 20, 2024

    Read time: 7 min

    Key takeaways
    Overview

    On December 3, 2024, the US Food and Drug Administration (FDA) published final guidance titled, Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions.

    The guidance finalizes core concepts of predetermined change control plans (PCCPs), which manufacturers of artificial intelligence (AI)-enabled medical devices can leverage to avoid having to create new marketing submissions each time they wish to significantly modify their devices following 510(k) clearance, de novo authorization, or premarket approval.

    In depth

    Manufacturers are generally required to submit new marketing applications to the FDA for review when a software modification could significantly alter that device’s safety and effectiveness. PCCPs are supplemental documentation that manufacturers of medical devices may include as part of typical marketing submissions, and they provide manufacturers with an avenue to avoid that burdensome process entirely. Comprising at least three sections – a description of modifications, a modification protocol, and an impact assessment – PCCPs are intended to notify the FDA of anticipated modifications to a device that may alter its safety and effectiveness. If the FDA authorizes a manufacturer’s PCCP, that manufacturer can implement modifications in line with the PCCP without having to submit new marketing applications.

    The FDA specifies that a device manufacturer stays within the bounds of an authorized PCCP when it:

    • Only implements modifications contemplated by the relevant PCCP
    • Deploys the authorized modifications in a manner that is consistent with the relevant PCCP.

    The final guidance finalizes previous draft guidance, which we covered in April 2023, and clarifies the FDA’s view of PCCPs in the AI-enabled medical device context. The guidance also discusses how manufacturers should leverage the PCCP process and the content that should be included in their PCCPs. Because many of the FDA’s substantive recommendations remain unchanged from the draft guidance, this On the Subject highlights changes that the FDA made in the final guidance, rather than providing a comprehensive outline of the guidance’s contents. Affected manufacturers should review the final guidance to see the FDA’s full suite of suggestions.

    Definitions

    The FDA broadened the scope of its guidance to cover all AI-enabled medical devices, rather than just machine-learning-enabled devices, a subset that the draft guidance focused on exclusively.

    In keeping with this change, the FDA defines terms such as “artificial intelligence” and “machine learning”:

    • Artificial Intelligence: “A machine based system that can, for a given set of human-defined objectives, make predictions, recommendations, or decisions influencing real or virtual environments. Artificial intelligence systems use machine- and human-based inputs to perceive real and virtual environments; abstract such perceptions into models through analysis in an automated manner; and use model inference to formulate options for information or action.”
    • Machine Learning: “A set of techniques that can be used to train AI algorithms to improve performance at a task based on data.”

    General Changes to the Guidance

    Throughout the guidance, the FDA added recommendations that manufacturers consider the unique characteristics of their device’s intended use populations (such as ethnicity, gender, and disease severity) and intended environments in their PCCP.

    The FDA also newly recommends that manufacturers update a device’s labeling and public-facing documents as the device is modified. Suggested updates include detailing when modifications are implemented, describing how they were implemented, and explaining how users were informed of the modifications.

    Components of a PCCP

    The recommended structure of a PCCP remains largely unchanged from the FDA’s previous draft guidance. The FDA still recommends that three sections specifically be included:

    • A description of modifications
    • A modification protocol
    • An impact assessment.

    Description of Modifications

    This section of the PCCP should generally “identify the specific, planned modifications” that the manufacturer intends to apply to the device following clearance or approval. The FDA has previously suggested what information should be included, such as descriptions of the planned modifications and modes of implementation.

    The FDA added to these recommendations in its final guidance, specifying that manufacturers are expected to detail the projected frequency of updates and raise effective guardrails against the range of automatic updates.

    Modification Protocol

    The FDA recommends that the modification protocol section of the PCCP detail “the methods that will be followed when developing, validating, and implementing modifications” described in the previous section.

    The final guidance recommends additional content that manufacturers should include in their PCCP submissions, such as:

    • Information on how to mitigate bias with respect to data-management practices
    • Information on how reference standards are determined, including when clinician interpretation is leveraged
    • Information on unresolvable failures in performance evaluation of a proposed modification
    • Information on the manufacturer’s post-market surveillance strategies, especially related to post-modification safety and effectiveness monitoring.
    • The FDA suggests that manufacturers adhere to their preexisting risk-management strategies when completing the modification protocol section of the PCCP.

    Impact Assessment

    In the impact assessment section of the PCCP, manufacturers should weigh the benefits and risks of using a PCCP for the device in question and discuss how the identified risks might be mitigated.

    In its final guidance, the FDA clarifies what information should be included in a PCCP for a combination product. Relevant considerations are:

    • How modifications to the device constituent part might impact the non-device constituent parts
    • How modifications to the device constituent part may affect the combination product in its entirety.

    The final guidance also revises the FDA’s previous recommendations on how the impact assessment should be structured. The FDA previously suggested that elements of the impact assessment could be incorporated freely into other sections of the PCCP where relevant. Although the final guidance still allows this practice, it specifies that clear references to that information must be included in the impact assessment section itself.

    Appendices

    As part of the guidance, the FDA provides two helpful resources to aid manufacturers in navigating the PCCP drafting process. First, the FDA lists a considerable number of sample questions for manufacturers to contemplate and discuss in their PCCP submissions. Second, the guidance provides several hypothetical scenarios that describe when PCCPs might be used in lieu of new marketing submissions. These include a new reference scenario related to a combination product titled, “Optical Imaging System Co-Packaged With Imaging Drugs.”

    Key Takeaways

    This final guidance provides a useful framework for manufacturers and developers to address projected modifications to AI-enabled medical devices. However, it also introduces potential implementation challenges that will require manufacturers to assess the impact of these recommendations on existing quality system processes such as design control, data management practices, risk management plans, adverse event reporting, and labeling.

    Manufacturers of AI-enabled medical devices should review the final guidance in its entirety to see if PCCPs might be useful in their marketing submission process. The FDA will host a webinar to answer questions about the final guidance on January 14, 2025.

    For more information on recent FDA guidance on AI in medical products, contact the authors of this article or any other member of McDermott’s Food, Drug & Medical Device Regulatory Group. Additional resources are also available on McDermott’s AI in Healthcare resource center.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Michael W. Ryan

    Partner

    Washington, DC

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    Henry Fisher

    Associate

    Washington, DC

    More insights

  • An end-of-year review of TTB tax audits and enforcement

    An end-of-year review of TTB tax audits and enforcement

    ARTICLE

    An end-of-year review of TTB tax audits and enforcement

    Dec 20, 2024

    Read time: 9 min

    Key takeaways
    Overview

    We have updated and republished this March 2024 blog post for a year-end summary.

    The Alcohol and Tobacco Tax and Trade Bureau’s (TTB) Office of Field Operations is responsible for ensuring industry members comply with the Federal Alcohol Administration Act, the Internal Revenue Code, and all related regulations. It is divided into three groups: the Trade Investigations Division (TID), the Tax Audit Division (TAD), and the Intelligence Division.

    Many industry members are most familiar with the TID, as it is comprises investigators who are responsible for enforcing compliance with the trade practice laws and maintaining a level playing field. The TAD may be less familiar, however, as it is comprises auditors who are responsible for ensuring payments of excise taxes and compliance with the laws and regulations in a manner that protects revenue and prevents unlawful activity in the commodities that the TTB regulates. The TAD works with other areas of the TTB and has the resources to assist in the investigations of underpayment of tax or other financial areas that relate to the laws and regulations enforced by the TTB. The TAD also performs random audits, which means that every industry member is susceptible to an audit.

    Over the past year, the TAD has issued a number of tax-related citations for failure to timely file and/or pay taxes, use of inappropriate tax rates, largely stemming from the improper use of reduced tax rates under the Craft Beverage Modernization Act (CBMA) and late payments, among other violations. TTB routinely resolved these violations by accepting offer-in-compromise (OIC) settlement payments from the targeted industry members, collectively, to the tune of approximately $11,000,000 since the beginning of 2023.

    Based on a review of the OICs, which are published on the TTB website, there were a wide range of tax-related violations over the past year, including:

    • Failure to timely file and/or pay taxes and reports. These failures accounted for nearly 70% of all OIC violations and have been a source of increasing scrutiny by TTB in 2024. In these common infringements, the permittee submits their reports or taxes late. The causes for a violation can range from (1) a simple late submission, even 1-2 days late; (2) filing the tax return without paying the taxes; (3) late payments due to processing times; or (4) a change in filing frequency. It is important to ensure that industry members’ reports are filed on time (even a day late is sufficient to warrant a violation) and that the taxes are paid promptly.
    • Use of inappropriate tax rates. There are two main categories of tax rate violations: (1) inappropriate use of reduced tax rates or credits, largely through improper use of the CBMA, and (2) inappropriate categorization of the product (commonly wine). An accurate determination of the product’s tax class is crucial to avoiding these violations, as is consideration of your eligibility (and continued eligibility) for CBMA-reduced rates or credits, including your status in a single taxpayer designation or a controlled group. We saw a significant increase in tax-related enforcement due to violations from acquisitions completed in the first half of the year, which impacted eligibility of the reduced tax rates for the entity as a new member of a controlled group. See our prior post on this topic.
    • Operating without a permit. The TTB accepts an offer-in-compromise one to two times a year from entities performing certain operations without the appropriate permit. For example, manufacturing, aging, warehousing, or bottling products on unpermitted premises or importing products without the appropriate licenses.
    • Failure to maintain adequate records. This citation is frequently connected with removal of the product from the bonded premises without the appropriate records or with insufficient bond coverage. The TTB has specific recordkeeping requirements for each commodity throughout the manufacturing, removal, and distribution processes. Failure to maintain these records can result in financial penalties.
    • Failure to report a timely change in ownership, management, or control. Reporting changes after initial qualification for licensure is a very important compliance requirement. Last year, we saw an increase in the TTB’s enforcement against industry members that failed to report changes in control or changes in proprietorship within 30 days of the change. The statutory consequence for failing to report a change is the automatic termination of the federal basic permit; therefore, the timely reporting of new ownership changes and due diligence of any prior changes is critical. All changes should be filed in a timely manner to keep your records updated and in compliance.
    • Failure to pay taxes via the appropriate method. The TTB requires that certain groups pay excise taxes through an electronic funds transfer. Occasionally, a change in ownership or in single taxpayer status can affect an entity’s required payment method. It is important to consider the impact that any organizational or operational changes may have on your entity’s payment requirements.

    Maintaining compliance with the applicable laws and regulations is important in order to avoid high financial penalties and costly administrative actions that could potentially put business operations in jeopardy. The TTB will continue to maintain a strong focus on tax audits for the near future. Our alcohol regulatory team is committed to helping you through an audit, consulting on any changes in your alcohol beverage operations, or representing you in matters involving the TTB.

    Authors

    Alva C. Mather

    Partner

    Washington, DC

    Christine Dower

    Counsel

    Washington, DC

    Michelle L. Draper

    Senior Alcohol Regulatory Specialist

    Wilmington

    More insights
    Endnotes

  • SIAC Rules 2025: Enhancing Efficiency and Transparency in Arbitration

    SIAC Rules 2025: Enhancing Efficiency and Transparency in Arbitration

    ARTICLE / CLIENT ALERT

    SIAC Rules 2025: Enhancing Efficiency and Transparency in Arbitration

    December 20, 2024

    Read time: 8 min

    Key takeaways
    Overview

    The Singapore International Arbitration Centre (SIAC) has unveiled the seventh edition of its arbitration rules, set to take effect on January 1, 2025 (the SIAC Rules 2025). These updated rules represent a significant step forward in enhancing the efficiency and transparency of arbitration proceedings, underscoring SIAC’s dedication to modernizing and optimizing the arbitral process. The revisions reflect extensive consultations with a diverse group of stakeholders, including arbitration practitioners, corporate entities, and government representatives.

    Complementing the SIAC Rules 2025 are two key developments: the revised Schedule of Fees and the proposed SIAC Insolvency Arbitration Protocol. Below, we outline some of the most notable innovations introduced in the SIAC Rules 2025 and the draft SIAC Insolvency Arbitration Protocol, which is currently open for public consultation.

    In depth

    Accelerated Proceedings

    Streamlined Procedure: One of the most notable changes in the SIAC Rules 2025 is the introduction of the Streamlined Procedure, which applies to disputes valued at less than S$1 million or where the parties agree to its application prior to the constitution of the tribunal. This procedure mandates the appointment of a sole arbitrator and requires the award to be rendered within three months. Designed for maximum efficiency, it excludes document production and witness evidence unless deemed necessary by the tribunal. Additionally, costs are capped at 50% of the maximum limits under the Schedule of Fees, making it a cost-effective option for resolving lower-value disputes. This procedure is particularly advantageous for straightforward cases where a swift resolution is desired.

    Expedited Procedure: The threshold for the Expedited Procedure has been raised from S$6 million to S$10 million. This procedure, which also involves a sole arbitrator, requires that the award be issued within six months of the constitution of the tribunal. Crucially, the new rules provide that a hearing must be held if the tribunal so decides or if any party requests a hearing, thus ensuring that the expedited procedure does not compromise the parties’ right to be heard. The Expedited Procedure is designed for cases that, while more complex than those suitable for the Streamlined Procedure, would still benefit from a more expeditious resolution process.

    Emergency Arbitrator Procedure: Significant improvements have been made to the Emergency Arbitrator Procedure. Parties may now request the appointment of an Emergency Arbitrator before filing a Notice of Arbitration, which must then be filed within seven days of the request. The new rules also introduce the possibility of obtaining protective preliminary orders on an ex parte basis, with decisions on such applications required within 24 hours. The ability to seek emergency relief before the formal commencement of arbitration proceedings addresses a critical need for immediate action in certain situations.

    Procedural Innovations Aimed at Increasing Efficiency

    Administrative Conference (Rule 11): The new rules authorize the SIAC Registrar to conduct administrative conferences to resolve procedural or administrative issues before the tribunal is constituted. This provision is designed to resolve preliminary issues efficiently and ensure a smooth arbitration process once the tribunal is constituted. These conferences facilitate the clarification of procedural steps and the early resolution of any administrative concerns and reflect a practice already implemented by some other arbitral institutions (such as the American Arbitration Association and the International Centre for Dispute Resolution).

    Coordinated Proceedings (Rule 17): Rule 17 introduces a mechanism for the coordinated resolution of multiple arbitrations involving common legal or factual issues and the same tribunal. This complements Rule 16, which provides for the consolidation of arbitrations related to the same legal relationships or underlying transactions in instances where the arbitration agreements are compatible. Rule 17 allows for concurrent or sequential hearings, procedural alignment, or the suspension of arbitrations pending decisions in other arbitrations. This innovation aims to streamline the resolution of complex, multifaceted disputes and reduce the risk of inconsistent outcomes. It is particularly useful in cases involving multiple contracts or parties, where coordination can significantly improve efficiency and reduce the risk of conflicting outcomes. For instance, disputes that arise from different transactions and involve different parties but are governed by the same standard agreements (e.g., a platform’s terms and conditions) could, in some instances, benefit from coordinated proceedings.

    Preliminary Determination (Rule 46): Rule 46 explicitly empowers tribunals to make preliminary determinations on certain issues early in the proceedings. This mechanism is intended to save time and costs by resolving threshold issues that may expedite the overall resolution of the dispute. Applications for preliminary determinations can be made with the consent of the parties if the requesting party can demonstrate efficiency benefits or if the circumstances of the case warrant such a determination. The tribunal is required to issue its decision within 90 days of the application. This provision formalizes a practice that has been used informally and provides clear guidelines for its application.

    Timeline for Awards (Rule 53): To provide greater certainty, the SIAC Rules 2025 now require tribunals to submit draft awards within 90 days of the last directed oral or written submission, unless the SIAC Registrar determines otherwise. This firm timeline aims to help parties manage their expectations and plan accordingly. Additionally, the rules require tribunals to provide an estimate of the time needed to issue an award within 30 days of the last oral or written submission, which further enhances predictability.

    Other Innovations

    Third-Party Funding (Rule 38): The SIAC Rules 2025 include comprehensive provisions regarding third-party funding. Parties are now required to disclose the existence of any third-party funding agreements and the identity of the funders. The tribunal can order the disclosure of details of the funding arrangement and take such arrangements into account when apportioning costs. This is particularly relevant in determining whether the third-party funder has undertaken to assume adverse cost liability. In addition, the rules prevent parties from entering into third-party funding agreements that may create conflicts of interest after the tribunal has been constituted. Rule 38 reflects the guidance on third-party funding previously set out in the SIAC’s Practice Note on Cases Involving External Funding.

    Security for Costs and Claims (Rules 48 and 49): The SIAC Rules 2025 contain explicit provisions on the ordering of security for costs and claims, thus eliminating ambiguities in the previous rules. The rules clarify that security for costs can only be ordered against parties asserting claims, counterclaims, or cross-claims.

    Draft SIAC Insolvency Arbitration Protocol

    A few days after releasing the SIAC Rules 2025, SIAC also released a draft Insolvency Arbitration Protocol for public consultation. Designed to address disputes arising from or in anticipation of insolvency proceedings, the Protocol adapts SIAC Rules to provide a structured, efficient, and time-sensitive framework for arbitration in insolvency contexts. The Protocol is a novel initiative by an international arbitration institution, encouraging the use of arbitration to resolve insolvency-related disputes and claims.

    The Protocol applies when parties agree to its use, whether before a dispute arises, during insolvency proceedings, or upon the recommendation of a court or insolvency professional. Significant procedural changes include reducing the time for responding to a notice of arbitration to seven days and requiring the appointment of the tribunal within 14 days. Final awards must be issued within six months of the constitution of the tribunal, which is in line with SIAC’s Expedited Procedure.

    Unless otherwise agreed, the seat of arbitration is Singapore, and Singapore law governs the arbitration agreement. Generally, a sole arbitrator is appointed, unless complexity or other circumstances warrant three arbitrators. Arbitrators may be selected from SIAC’s forthcoming Specialist Insolvency Disputes Panel, which will  be composed of experts in the field.

    The Protocol encourages mediation and allows arbitration to be suspended for up to three weeks to facilitate settlement discussions. Successful mediations may lead to consent awards, provided the terms are consistent with applicable law, public policy, and the jurisdiction of the tribunal. Tribunals are also encouraged to consider joining additional parties at the outset. It is not yet clear how this provision will play out in practice, particularly where the party the tribunal seeks to join does not consent.

    To facilitate coordination with insolvency proceedings, parties may request anonymized or redacted awards for disclosure and share arbitration updates as needed. By addressing the unique challenges of insolvency-related disputes, the Protocol aims to enhance procedural efficiency and ensure effective resolution in these complex cases.

    Embracing an Efficient Path Forward

    The SIAC Rules 2025 represent a significant step forward in the evolution of international arbitration. By introducing new procedures and enhancing existing mechanisms, these rules aim to make arbitration more efficient, transparent, and user-friendly. Parties to SIAC-administered arbitrations can expect a streamlined and modernized process that upholds the highest standards of arbitral integrity. The comprehensive updates ensure that SIAC remains at the forefront of international arbitration, providing a robust framework for the fair and efficient resolution of disputes. Similarly, the draft Insolvency Arbitration Protocol is a groundbreaking initiative by an international arbitration institution, promoting the use of arbitration to resolve insolvency-related disputes and claims.

    At McDermott, our exceptionally skilled international arbitration practitioners have developed substantial experience in international arbitration, including under the SIAC Rules. We are well-equipped to navigate the complexities of international commercial arbitration and its ever-evolving rules, delivering bespoke and efficient legal solutions tailored to your specific requirements worldwide.

    For further assistance with arbitration matters or advice, please contact any of the authors or your regular McDermott lawyer.

    Authors

    Lisa M. Richman

    Partner

    Washington, DC

    Maria Cristina Rosales del Prado

    Special Legal Consultant

    Washington, DC

    Maxime Delabarre

    Associate

    Paris

    More insights

  • Complying with the ‘relevant data’ requirement under the final 2024 Mental Health Parity and Addiction Equity Act: A proposal for a workable alternative

    Complying with the ‘relevant data’ requirement under the final 2024 Mental Health Parity and Addiction Equity Act: A proposal for a workable alternative

    ARTICLE

    Complying with the ‘relevant data’ requirement under the final 2024 Mental Health Parity and Addiction Equity Act: A proposal for a workable alternative

    December 19, 2024

    Read time: 4 min

    The Mental Health Parity and Addiction Equity Act (MHPAEA) generally requires group health plans and health insurance issuers to ensure that financial requirements (such as copays and deductibles), quantitative treatment limitations (such as visit limits), and nonquantitative treatment limitations (such as prior authorization and concurrent review) applicable to mental health or substance use disorder (MH/SUD) benefits are generally no more restrictive than the requirements or limitations applied to medical/surgical (M/S) benefits. The Consolidated Appropriations Act, 2021 imposed further obligations in the case of nonquantitative treatment limitations (NQTLs), which are the subject of final regulations issued in September 2024. (We explained the final regulations in a September 2024 client alert.)

    Among many other things, the final regulations establish a two-part test that applies to NQTLs consisting of:

    • The design and application requirement. This test requires that the processes, strategies, evidentiary standards, or other factors used in designing and applying an NQTL to MH/SUD benefits in each classification must be comparable to and applied no more stringently than those used in designing and applying the limitation with respect to M/S benefits in that same classification. For this purpose, classifications include inpatient, in-network care; inpatient, out-of-network care; outpatient, in-network care; outpatient, out-of-network care; emergency care; and prescription drugs.
    • The relevant data evaluation requirement. This test requires the plan or issuer to collect and evaluate relevant data in a manner reasonably designed to assess the impact of the NQTL on relevant outcomes related to access to MH/SUD benefits as compared to M/S benefits. Relevant data for this purpose includes the number and percentage of relevant claims denials and network composition data.

    The relevant data evaluation requirement has proven especially challenging for self-funded group health plans of every size, as third-party administrators fail, refuse, or are otherwise unable to provide the information necessary to comply. There may be another option, however.

    The final regulations do not specify the data set on which compliance with the relevant data requirement is tested. Rather, the regulations, which apply to both plans and issuers, seem to assume that the plans test on the basis of plan data, and issuers test on the basis of the issuer’s corresponding block of business. In their informal remarks at trade and industry conferences, representatives of the US Department of Labor (DOL), expressing their own views and not those of the DOL, have acknowledged that they are aware of and are considering their options related to the proper testing data set.

    Some large carriers have shared the NQTL analysis that they previously prepared for their fully insured groups with the self-funded group to whom they provide administrative services. Presumably, this will give their self-funded groups a starting point. Many self-funded groups, particularly smaller groups, are not inclined to modify the standard set of NQTLs offered by their carriers/administrative-service-only (ASO) providers. If these groups were allowed to test based on the carrier’s corresponding book of business, a good deal of the work would be done. This would also have the salutary effect of exerting market pressure on carriers to comply with the MHPAEA’s NQTL and other requirements, since failure to do so would cause multiple additional failures. In the case of smaller plans, whose data may not be significant, this approach would also ensure that testing is done on a statistically significant sample. The option of designing custom NQTLs is, as a practical matter, reserved for larger self-funded groups. But even here, plans might simply modify a carrier’s standard NQTLs to the extent necessary to reflect the modification. Thus, even these groups might benefit from being able to leverage the carrier’s/ASO provider’s standard NQTL analysis with an appropriate, custom supplement.

    For MHPAEA purposes, plans and carriers are the regulated entities. It is, however, painfully obvious that plan administrators rely heavily, if not exclusively, on their ASO providers and other advisors to comply. Using the carrier’s data for purposes of complying with (or at least undergirding) the plans’ NQTL analysis makes a good deal of sense. In both the preamble to the final regulations and in the public comments of its representatives, the DOL has promised additional guidance to help plans and issuers comply with the final regulations. This includes, among other things, an updated self-compliance tool. Clarification that the plans can choose to comply with the relevant data requirement by using their ASO provider’s data set would be welcome.

    More insights